Phentermine Alternatives Are Long-Term Drugs and OTC alli
Long-term prescription medications and over-the-counter orlistat provide ongoing alternatives to short-term phentermine across separate clinical trials.
Phentermine is labeled for only a few weeks, so the alternatives are the long-term prescription drugs and one OTC pill. Those prescription alternatives are Wegovy, Zepbound, Qsymia, Contrave, Saxenda, and Xenical, alongside over-the-counter alli. At The Metabolic Journal, we turn the research into steps a person can follow. We tabulated the primary FDA package inserts and manufacturer documents. While Adipex-P and Lomaira are indicated for short-term use, prescription alternatives are indicated for chronic weight management. Our pages phentermine vs tirzepatide and Qsymia vs Wegovy compare two pairs in more detail.
No clinical trial has evaluated all of these weight-management options in a single head-to-head study. Instead, each drug was studied against a placebo in separate pivotal registration programs spanning 56 to 72 weeks. The documented weight reductions ranged from roughly -5% with Contrave to approximately -21% with the 15 mg dose of Zepbound in separate pivotal trials.
Phentermine Alternatives at a Glance
When a phentermine course ends after a few weeks, the labeled long-term options are Wegovy, Zepbound, Qsymia, Contrave, Saxenda, and Xenical, alongside OTC alli. A prescriber decides whether any change is appropriate. The available prescription alternatives include injectable GLP-1 and dual GIP/GLP-1 receptor agonists, oral fixed-dose combinations, and gastrointestinal lipase inhibitors, alongside one over-the-counter option. In our comparison of phentermine alternatives, we lined up official package inserts, including the Wegovy May 2026 label, Zepbound April 2026 label, Qsymia March 2026 label, Contrave 2025 label, Adipex-P March 2024 label, Lomaira December 2023 label, and the alli March 2026 Drug Facts update.
| Medication | Drug Class and Format | FDA Approved Duration | Pivotal Trial Weight Loss (Placebo) | Key Safety Warnings |
|---|---|---|---|---|
| Phentermine | Oral tablet (Adipex-P 37.5 mg, Lomaira 8 mg), Schedule IV | Short-term (a few weeks) | No phentermine trial figures are reported here | Contraindicated in cardiovascular disease, glaucoma, hyperthyroidism; blood pressure elevation |
| Wegovy | GLP-1 receptor agonist; weekly subcutaneous injection or daily oral tablet | Chronic weight management (long term) | -14.9% vs -2.4% (injection, 68 wks); -13.6% vs -2.4% (pill, 64 wks) | Boxed warning for thyroid C-cell tumor risk; pancreatitis, gallbladder disease, severe GI events |
| Zepbound | GIP and GLP-1 receptor agonist; weekly subcutaneous injection | Chronic weight management (long term) | -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% (72 wks) | Boxed warning for thyroid C-cell tumor risk; severe GI adverse reactions, acute kidney injury |
| Qsymia | Phentermine plus topiramate extended-release; oral once daily in the morning (Schedule IV) | Chronic weight management (long term) | -9.8% (15 mg/92 mg), -7.8% (7.5 mg/46 mg) vs -1.2% (56 wks) | Embryo-fetal toxicity requiring REMS and monthly pregnancy tests; acute myopia and glaucoma |
| Contrave | Naltrexone HCl and bupropion HCl extended-release; daily oral tablets | Chronic weight management (long term) | -5.4% vs -1.3% (56 wks, COR-I); -8.1% vs -4.9% (COR-BMOD) | Boxed warning for suicidal thoughts and behaviors; contraindicated in seizure disorders and uncontrolled hypertension |
| Saxenda | Not published | Chronic weight management (long term) | Evaluate at 16 weeks; discontinue if under 4% baseline weight loss per label | Boxed warning for thyroid C-cell tumor risk; contraindicated with personal or family history of MTC or MEN 2 |
| Xenical / alli | Gastrointestinal lipase inhibitor; oral capsule taken with meals | Weight management and maintenance (Rx) or OTC weight loss aid | 3% mean difference vs placebo at 1 year (completers: 57% lost >=5%) | GI adverse events (oily spotting, fecal urgency); kidney stone and kidney injury risk warnings |
Because these medications were examined in separate clinical programs rather than a direct head-to-head investigation, reported percentage changes cannot be compared directly to establish numerical superiority. Instead, separate trials reported the largest mean weight loss with Zepbound and Wegovy and smaller losses with Contrave and orlistat. A licensed healthcare provider must evaluate individual cardiovascular health, medical history, budget, and therapy goals before recommending any transition.
What the Phentermine Labels Say
Phentermine hydrochloride is approved as a short-term adjunct for a few weeks in a weight-reduction regimen based on exercise, behavioral modification, and caloric restriction. The medication is indicated for adults with an initial body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of risk factors such as controlled hypertension, diabetes, or hyperlipidemia. Brands such as Adipex-P supply a 37.5 mg tablet taken once daily, while Lomaira provides an 8 mg tablet taken three times daily before meals.
Phentermine is classified as a Schedule IV controlled substance. Adipex-P labeling lists adverse reactions that include heart palpitations, tachycardia, elevation of blood pressure, ischemic events, primary pulmonary hypertension, valvular heart disease, restlessness, insomnia, tremor, dizziness, headache, and psychosis. Phentermine is contraindicated in patients with any history of cardiovascular disease, including coronary artery disease, stroke, cardiac arrhythmias, congestive heart failure, and uncontrolled hypertension. It is also contraindicated during or within 14 days of monoamine oxidase inhibitors (MAOIs), in hyperthyroidism, glaucoma, agitated states, a history of drug abuse, pregnancy, and nursing.
Wegovy, Zepbound and Saxenda
GLP-1 and dual GIP/GLP-1 receptor agonists represent long-term injectable and oral options prescribed for chronic weight management. Unlike phentermine, these medications carry FDA clearance to reduce excess body weight and maintain that weight reduction long term in adults with obesity, or overweight accompanied by at least one weight-related comorbidity. Patients comparing options can read our comparison of Wegovy vs Zepbound.
Wegovy is a GLP-1 receptor agonist supplied as both a weekly subcutaneous injection and a daily oral tablet in its May 2026 label. Injectable Wegovy begins at 0.25 mg weekly and escalates to a 2.4 mg maintenance dose, with an approved 7.2 mg Wegovy HD dose also included in the label. In the 68-week STEP 1 trial (Study 2) published by Wilding et al. in NEJM involving 1,961 adults without type 2 diabetes, Wegovy 2.4 mg demonstrated a mean weight reduction of 14.9% compared to 2.4% for placebo, with 83.5% of patients losing at least 5% of their starting weight. Oral Wegovy tablets (25 mg daily maintenance taken on an empty stomach with up to 4 ounces of water) achieved a 13.6% mean loss versus 2.4% for placebo across 64 weeks in Study 7. Wegovy is also approved to reduce major adverse cardiovascular events (MACE) risk in adults with established cardiovascular disease and obesity or overweight.
Zepbound is a dual GIP and GLP-1 receptor agonist administered subcutaneously once weekly across doses escalating from 2.5 mg up to 15 mg. Zepbound is indicated for chronic weight management as well as moderate-to-severe obstructive sleep apnea in adults with obesity. In the 72-week SURMOUNT-1 trial (Study 1) of 2,539 adults without diabetes, tirzepatide produced mean weight reductions of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared to 3.1% for placebo. Among participants on the 15 mg dose, 90.9% achieved at least 5% weight loss.
Saxenda (liraglutide) is labeled for chronic weight management. The Saxenda label says to evaluate at 16 weeks and discontinue if an adult has not lost at least 4% of baseline body weight. All three incretin options carry a boxed warning regarding the risk of thyroid C-cell tumors based on rodent findings, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both Wegovy and Zepbound had warnings for suicidal behavior and ideation removed by the FDA in early 2026, leaving warnings focused on acute pancreatitis, acute gallbladder disease, severe gastrointestinal reactions, and acute kidney injury from volume depletion.
Qsymia and Contrave
Both Qsymia and Contrave combine two active ingredients into an extended-release daily regimen.
Qsymia combines phentermine hydrochloride with topiramate extended-release taken orally once daily each morning. Because it retains phentermine, Qsymia is designated as a Schedule IV controlled substance. In the 56-week CONQUER trial (Study 2), Qsymia achieved mean weight reductions of 7.8% on 7.5 mg/46 mg and 9.8% on 15 mg/92 mg, compared to 1.2% for placebo. Among high-dose patients, 70% lost at least 5% of their initial weight. In Study 1 (EQUIP), patients with a BMI of 35 or greater achieved a 10.9% reduction on the maximum dose versus 1.6% for placebo.
Qsymia carries reproductive safety warnings. Due to embryo-fetal toxicity and the risk of fetal harm, Qsymia is available only through a limited program under a REMS. Patients of reproductive potential must obtain a negative pregnancy test before starting treatment and undergo documented monthly pregnancy testing. Common adverse reactions include paresthesia, dysgeusia, dizziness, insomnia, constipation, and dry mouth, alongside warnings for acute myopia, angle closure glaucoma, metabolic acidosis, and cognitive impairment.
Contrave combines naltrexone hydrochloride, an opioid antagonist, with bupropion hydrochloride, an aminoketone antidepressant, in an extended-release oral tablet. In the 56-week COR-I trial, Contrave produced a mean weight reduction of 5.4% at the maintenance dose (32 mg naltrexone / 360 mg bupropion daily) compared to 1.3% for placebo, with 42% of participants achieving at least 5% weight loss. In COR-BMOD, weight loss reached 8.1% versus 4.9% for placebo. Before week 56, 46% of Contrave patients and 45% of placebo patients withdrew. About 24% vs 12% discontinued for an adverse reaction.
Contrave carries a boxed warning regarding suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants, and it is not approved for pediatric patients. It is contraindicated in patients with uncontrolled hypertension, seizure disorders, anorexia or bulimia, abrupt withdrawal from alcohol or sedatives, concurrent chronic opioid use, or other bupropion-containing medications. Contrave can also trigger false-positive results on urine amphetamine screening tests.
Orlistat
Xenical is a reversible inhibitor of gastrointestinal lipases. Orlistat is available as prescription Xenical (120 mg capsules taken three times daily with fat-containing meals) and over-the-counter alli (60 mg capsules taken up to three times daily).
The FDA first approved Xenical in 1999 for obesity management, including weight loss, weight maintenance, and reducing regain. The Xenical label on the FDA site is the 01/2012 version, and the FDA notes it may not be the latest approved label. In one-year pooled clinical trial data published in the Xenical label, patients assigned to orlistat achieved a mean weight reduction of 13.4 pounds compared to 5.8 pounds for placebo, which represents a placebo-subtracted difference of approximately 3 percentage points. Among completers in those studies, 57% of Xenical patients achieved at least a 5% reduction in baseline body weight compared to 31% on placebo. Its package insert also documents long-term outcomes from the four-year XENDOS trial.
The primary clinical trade-off of orlistat involves its gastrointestinal tolerability profile. In year-one registration data, patients experienced digestive side effects: oily spotting (26.6% vs 1.3% placebo), flatus with discharge (23.9% vs 1.4%), fecal urgency (22.1% vs 6.7%), fatty or oily stools (20.0% vs 2.9%), and fecal incontinence (7.7% vs 0.9%). These adverse effects typically start within 3 months.
Xenical is contraindicated in chronic malabsorption syndrome, cholestasis, and pregnancy. The label warns to take a multivitamin with fat-soluble vitamins. The label also warns of rare cases of severe liver injury and increased risks of urinary oxalate formation and renal effects.
At the 60 mg dose, alli is recognized on the FDA Drug Safety Communication page as the only FDA-approved over-the-counter weight loss aid. The product is indicated for overweight adults 18 years and older following a reduced-calorie, low-fat diet. The alli Drug Facts list organ transplant, cyclosporine use, and problems absorbing food under "Do not use." A prescriber decides any change. On June 10, 2026, the FDA approved labeling revisions for alli warning consumers about potential risks of kidney stones and kidney injury. Aside from alli, the FDA warns on its weight loss product notifications page that non-prescription diet pills, fat-burners, and teas are not guaranteed to work and are likely to be contaminated with dangerous hidden ingredients.
Self-Pay Prices Published by Manufacturers
For Wegovy, Novo Nordisk publishes cash-pay options on its NovoCare savings page. Through December 31, 2026, the Wegovy pen self-pay offer is $199 per month for the first two monthly fills at 0.25 mg and 0.5 mg for patients new to the Savings Offer or NovoCare home delivery. Thereafter, the price rises to $349 per month for standard maintenance strengths (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg), while Wegovy HD (7.2 mg) costs $399 per month. For the oral Wegovy tablet, monthly 30-day supplies are priced at $149 for 1.5 mg, $199 for 4 mg, and $299 for both 9 mg and 25 mg strengths. While commercially insured patients may pay as little as $25 with a maximum savings benefit of $100 per month, government insurance beneficiaries are excluded from commercial savings cards, though they may access published self-pay pricing.
Zepbound KwikPen self-pay prices are tiered by dose: $299 per month for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, and 15 mg formulations. Patients utilizing the Zepbound savings card can reduce the 7.5 mg and higher doses to $449 per month, provided the next refill occurs within 45 days of the previous fill. According to the Qsymia savings page, the QsymiaEngage home delivery program offers a cash-only price of $74.99 per 30-day fill (approximately $2.50 daily), with 90-day fills available at $70 per month. Costco offers a 30-day cash price of $65.99. Commercial savings cards offer up to $75 off cash fills or $65 off insured copays exceeding $70, though government beneficiaries and residents of California and Massachusetts are excluded. For Contrave, the Contrave savings page advertises a cash price of $199 for 120 tablets, or $99 per month with free shipping through CurAccess. A telehealth consult program provides the medication for no more than $99 plus a $45 provider consultation fee. Contrave savings programs likewise exclude prescriptions paid by Medicare, Medicaid, Medigap, TRICARE, DOD, or VA programs.
Who This Is Not For, and What Would Change Our Answer
Certain medical conditions rule out specific options under their FDA labels. A prescriber decides any change. The Wegovy, Zepbound and Saxenda labels list a personal or family history of medullary thyroid carcinoma or MEN 2 as a contraindication. Phentermine, Qsymia, and Xenical are contraindicated in pregnancy, while the Wegovy label says to discontinue when pregnancy is recognized and to stop at least 2 months before a planned pregnancy. Contrave is contraindicated in uncontrolled hypertension, active seizure disorders, or chronic opioid use.
Published self-pay prices run from $65.99 to $699 a month for the drugs with a published price. Saxenda, Xenical and alli self-pay prices are not reported here. Our answer would change with updated labels or a direct head-to-head trial.
Our Takeaway on Phentermine Alternatives
If phentermine therapy ends after a few weeks and medical weight management must continue, the FDA-approved long-term options are Wegovy, Zepbound, Qsymia, Contrave, Saxenda, and Xenical, alongside over-the-counter alli. Separate pivotal trials were not head-to-head and are not directly comparable. They reported the largest mean weight reductions with Zepbound (up to 20.9% on 15 mg) and Wegovy (14.9% on 2.4 mg). Smaller average reductions were documented for Qsymia (up to 9.8%), Contrave (5.4%), and orlistat (a placebo-subtracted difference of approximately 3 percentage points).
Based on our tabulation of FDA package inserts and manufacturer savings pages, fit depends on personal cardiovascular history, reproductive plans, tolerance for gastrointestinal or neurological adverse effects, and monthly out-of-pocket budget. The phentermine label states short-term use of a few weeks, whereas long-term agents require balancing boxed warnings for thyroid tumors or neuropsychiatric effects against continuous chronic treatment goals.
A licensed prescriber decides whether initiating or switching medications is clinically appropriate. To prepare for an informed discussion with your healthcare provider regarding your metabolic health and prescription phentermine alternatives, complete our free metabolic assessment.
Frequently Asked Questions
What drug mimics phentermine?
Qsymia is the approved prescription medication that directly contains phentermine as an active ingredient, combining phentermine hydrochloride with topiramate extended-release in a daily oral dose. While standard phentermine is labeled only for a few weeks of short-term use, Qsymia is FDA-approved for chronic weight management to maintain weight reduction long term. Because it contains phentermine, Qsymia is also classified as a Schedule IV controlled substance, and it is available only through a limited program under a REMS.
Why do doctors not like phentermine?
Phentermine's FDA label restricts its indication to short-term use of a few weeks and designates it as a Schedule IV controlled substance. Furthermore, phentermine is strictly contraindicated in patients with a history of cardiovascular disease (such as coronary artery disease, stroke, cardiac arrhythmias, congestive heart failure, and uncontrolled hypertension), hyperthyroidism, glaucoma, agitated states, and during or within 14 days of MAOI use. Its adverse reactions include blood pressure elevation, tachycardia, palpitations, restlessness, and insomnia.
What are the most effective weight loss pills?
Among oral prescription medications evaluated in clinical trials, oral Wegovy tablets (25 mg daily maintenance) demonstrated a mean weight reduction of 13.6% compared to 2.4% for placebo across 64 weeks in Study 7 of its FDA label. Qsymia achieved a 9.8% mean weight loss on the top dose (15 mg/92 mg) versus 1.2% for placebo at 56 weeks in the CONQUER trial, and Contrave tablets produced a 5.4% mean loss versus 1.3% for placebo at 56 weeks in the COR-I trial. These trials were conducted separately and cannot be compared directly head-to-head.
What is the number one weight loss pill over the counter?
alli (orlistat 60 mg) is the only FDA-approved over-the-counter weight loss aid, as documented by FDA Drug Safety Communications. It is indicated for overweight adults aged 18 and older alongside a reduced-calorie, low-fat diet. In June 2026, the FDA approved updated labeling for alli warning consumers about potential risks of kidney stones and kidney injury.
Do appetite suppressant pills really work?
Three labeled oral prescription drugs showed larger mean weight loss than placebo in separate trials. In Study 7, oral Wegovy tablets produced a 13.6% mean reduction at 64 weeks. Qsymia produced up to a 9.8% mean reduction at 56 weeks in Study 2, while Contrave produced a 5.4% mean reduction at 56 weeks in COR-I. The FDA states that non-prescription diet pills, fat-burners, and teas are not guaranteed to work and are likely to be contaminated with dangerous hidden ingredients.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Jardiance Alternatives: Other SGLT2 Inhibitors, GLP-1 Drugs and Metformin Compared on Approved Uses, Kidney Limits, Warnings and Generics.
Jardiance alternatives: other SGLT2 inhibitors, GLP-1 drugs and metformin compared on approved uses, kidney limits, warnings and generics.
-
Ozempic Alternatives: 7 Options Compared (Prescription, Compounded & Natural)
Ozempic alternatives ranked: other GLP-1 drugs, compounded options, metformin, berberine, and lifestyle-first care.
-
Metformin Alternatives: 6 Prescription and Natural Options Compared
Metformin alternatives ranked: GLP-1s, SGLT2 inhibitors, pioglitazone, berberine, inositol, lifestyle.
See more related comparisons
-
Zepbound Alternatives: 6 Options Compared for Weight Management
Zepbound alternatives ranked: Wegovy, Mounjaro, off-label Ozempic, compounded GLP-1, metformin.
-
Wegovy Alternatives: 6 Options Compared for Weight Management
Wegovy alternatives ranked: Zepbound, off-label Ozempic, compounded semaglutide, metformin, lifestyle.
-
Mounjaro Alternatives: 6 Options Compared for 2026
Mounjaro alternatives ranked: Zepbound, Ozempic/Ozempic tablets, compounded tirzepatide, metformin, lifestyle.
-
Rybelsus Alternatives: What Replaced Rybelsus and 5 Other Options Compared
Rybelsus alternatives ranked: Ozempic tablets, the Wegovy pill, injectable semaglutide, tirzepatide, metformin.
-
Phentermine vs Tirzepatide: Which Loses More Weight, on Trial Results, Mechanism, and Cost
Phentermine vs tirzepatide: trial weight-loss data, mechanism, cost, and the cost-per-pound-lost math compared.